PsychoGenics is a renowned brand committed to collaborating with various organizations and institutions to aid in the discovery of new treatments. With over 20 years of experience in the field, PsychoGenics has built a reputation for high-capacity and high-quality testing, delivering fast turnaround and accurate results. They offer a wide range of services, including animal models, behavioral tests, bioanalysis and microdialysis, immunohistochemistry, molecular biology, electrophysiology, and more.

These services enable the evaluation and understanding of various neuropsychiatric disorders such as Alzheimer's disease, epilepsy, Parkinson's disease, depression, and schizophrenia. PsychoGenics' team of talented scientists has also developed innovative AI-driven drug discovery platforms and analytical tools, leading to shared-risk partnerships and the development of numerous drug candidates currently in clinical trials. Their fee-for-service and partnered research have contributed significantly to the advancement of treatments for patients suffering from severely disabling neuropsychiatric disorders.

Trust in PsychoGenics' expertise and dedication to improve patients' lives